Page 1689 - Clinical Small Animal Internal Medicine

Index 1627

persistent right aortic arch PHPTH see primary PLE see protein‐losing enteropathy
VetBooks.ir personal protective equipment (PPE) physiologic shunting 384–385 pleural effusion 333–344
hyperparathyroidism
(PRAA) 562
pleocytosis 798
fungal infections 988
airway and lung cancers 1279
pilomatricoma 1355
kennels and multicat pituitary–adrenal axis 55 anatomy and physiology
environments 1064–1066 pituitary‐dependent 333–334, 334
leptospirosis 948–949 hyperadrenocorticism bilothorax 343
mycobacteriosis 984 (PDH) 49–63 canine myocardial disease 255
nocosomial and multidrug‐resistant adrenal‐directed therapies cardiovascular disease 125
infections 1061 57–61, 58 chylothorax 338, 341–343, 342
yersiniosis 954 baseline diagnostics 53 clinical signs and physical
PET see positron emission tomography classification 49, 50 examination 335, 336
PF see pemphigus foliaceus diagnosis 53–57, 53–54 diagnosis 336–338
P:F ratio 379 diagnosis and evaluation of pleural fluid
P‐glycoprotein 634 treatment 1213–1214 337–339, 337
PH see portal hypertension; pulmonary differential diagnosis 55, 56 hemothorax 343
hypertension etiology/pathophysiology 1213 imaging techniques 336–337, 340
pharmacocardiology 469 etiology/pathophysiology and monitoring pleural pressure 335,
pharyngeal phase dysphagia 474 epidemiology 49–52 338–339
pharyngeal tumors 1258 feline acromegaly 45 pathophysiology of pleural fluid
pharynx history and clinical signs accumulation 334–335, 335
assessment of pharyngeal 52–53, 52 pulmonary thromboembolism 313
function 473–474 metabolic diseases 677–678 pyothorax 337, 339–341, 340
gastrointestinal imaging 473–474 pathogenesis 50–52 respiratory pattern‐based approach
normal anatomy and examination pituitary‐directed therapies 58, to dyspnea 291
technique 473 61–63 specific pleural fluid tests 338
ultrasonography 473 prevalence 49–50 surgical approaches to thoracic
phlebotomy 1215 prognosis 63 disease 326–327, 328, 330
phosphate urolithiasis 1129–1130, surgical treatment 57, 62–63 thoracoscopy 339, 339
1142–1143 treatment 57–63, 58 transudative and exudative
phosphaturic mesenchymal tumor, pituitary gland 35–41, 36, 51 effusions 334, 337–338
mixed connective tissue variant pituitary macroadenomas 779 pleural filling disorders 382, 387
(PMT‐MCT) 1527 PL see patella luxation pleural space 291–292
phosphorus homeostasis and plague see yersiniosis PLN see protein‐losing nephropathy
disorders 1079–1085 plantigrade stance 96, 96 PLR see pupillary light reflex
acute kidney injury 1097 plaques 1406, 1504, 1504 PMI see point of maximum intensity
anatomy and physiology plasma aldosterone concentration PMT‐MCT see phosphaturic
1079, 1080 (PAC) 91 mesenchymal tumor, mixed
chronic kidney disease plasma‐based coagulation assays 317 connective tissue variant
1171, 1171 plasma cell disorders PN see parenteral nutrition
clinical signs 1082–1083 (PCD) 1241–1246 pneumatosis 484, 484
epidemiology of diagnosis 1243–1245, pneumocolonography 499
hyperphosphatemia 1084 1243–1244, 1243 pneumocytosis 1020
etiology/pathophysiology 1082, epidemiology 1242 pneumonia
1084–1085, 1084 etiology/pathophysiology mechanical ventilation 393, 400
hyperphosphatemia 1083–1085, 1241–1242, 1242 nocosomial and multidrug‐resistant
1097, 1171, 1171 history and clinical signs 1243 infections 1058
hypophosphatemia 1082–1083 prognosis 1246 respiratory pattern‐based approach
laboratory assessment 1081–1082 signalment 1242–1243 to dyspnea 292
metabolic bone diseases treatment 1245–1246 pneumothorax
1521–1527 plasma cell leukemia 1241–1246 head trauma 750–751
regulation of phosphorus plasmapheresis 1370–1371 mechanical ventilation 401
1079–1081, 1080, 1081 plasma proteins 649–650 pleural effusion 338
treatment 1083, 1085 plasma renin activity (PRA) 91 pulmonary thromboembolism 314
photodynamic therapy 1356 plateletpheresis 1369, 1372 respiratory pattern‐based approach
photopheresis 1370 Platynosomum spp. 721 to dyspnea 291–292